- Home
- AIMD vs ADXN Comparison
AIMD vs ADXN Comparison
Compare AIMD & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIMD
- ADXN
- Stock Information
- Founded
- AIMD 1984
- ADXN 2002
- Country
- AIMD United States
- ADXN Switzerland
- Employees
- AIMD N/A
- ADXN N/A
- Industry
- AIMD Biotechnology: Pharmaceutical Preparations
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- AIMD Health Care
- ADXN Health Care
- Exchange
- AIMD Nasdaq
- ADXN Nasdaq
- Market Cap
- AIMD 7.5M
- ADXN 8.2M
- IPO Year
- AIMD N/A
- ADXN N/A
- Fundamental
- Price
- AIMD $0.54
- ADXN $7.45
- Analyst Decision
- AIMD
- ADXN Strong Buy
- Analyst Count
- AIMD 0
- ADXN 1
- Target Price
- AIMD N/A
- ADXN $30.00
- AVG Volume (30 Days)
- AIMD 154.6K
- ADXN 7.7K
- Earning Date
- AIMD 03-07-2025
- ADXN 04-07-2025
- Dividend Yield
- AIMD N/A
- ADXN N/A
- EPS Growth
- AIMD N/A
- ADXN N/A
- EPS
- AIMD N/A
- ADXN 0.06
- Revenue
- AIMD $20,729.00
- ADXN $701,260.00
- Revenue This Year
- AIMD N/A
- ADXN N/A
- Revenue Next Year
- AIMD N/A
- ADXN N/A
- P/E Ratio
- AIMD N/A
- ADXN $0.89
- Revenue Growth
- AIMD N/A
- ADXN N/A
- 52 Week Low
- AIMD $0.40
- ADXN $6.67
- 52 Week High
- AIMD $1.46
- ADXN $27.90
- Technical
- Relative Strength Index (RSI)
- AIMD 51.16
- ADXN 47.90
- Support Level
- AIMD $0.46
- ADXN $7.16
- Resistance Level
- AIMD $0.57
- ADXN $8.05
- Average True Range (ATR)
- AIMD 0.05
- ADXN 0.45
- MACD
- AIMD 0.00
- ADXN -0.02
- Stochastic Oscillator
- AIMD 69.03
- ADXN 51.22
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.